Evidence map›Paper›PMID 40309792›Full record

ArticleBrain sciences2025

Real-World Case Series of Ravulizumab Use in Patients with Myasthenia Gravis in Romania.

Crisanda Vîlciu, Oana Antonia Mihalache, Bogdan Marius Istrate, Mihaela Aftinia Marian, Mirela Ramona Drăghici, Diana Mihaela Petrescu, Adriana Octaviana Dulămea, Daniela Cristina Anghel

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Brain sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Disease severity as the dominant clinic-available marker of myasthenic crisis occurrence: a single-centre retrospective study.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Crisanda VîlciuDepartment of Neurology, "Carol Davila" University of Medicine and Pharmacy, 020021 Bucharest, Romania.
Oana Antonia MihalacheDepartment of Neurology, "Fundeni" Clinical Institute, 022328 Bucharest, Romania.
Bogdan Marius IstrateIndependent Researcher, 3000 Leuven, Belgium.
Mihaela Aftinia MarianDepartment of Neurology, "Carol Davila" University of Medicine and Pharmacy, 020021 Bucharest, Romania.
Mirela Ramona DrăghiciDepartment of Neurology, "Fundeni" Clinical Institute, 022328 Bucharest, Romania.ORCID 0000-0001-6738-9186
Diana Mihaela PetrescuDepartment of Neurology, "Carol Davila" University of Medicine and Pharmacy, 020021 Bucharest, Romania.
Adriana Octaviana DulămeaDepartment of Neurology, "Carol Davila" University of Medicine and Pharmacy, 020021 Bucharest, Romania.ORCID 0000-0002-5056-0191
Daniela Cristina AnghelDepartment of Neurology, "Carol Davila" University of Medicine and Pharmacy, 020021 Bucharest, Romania.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

MG-ADLMG-QoL15rmyasthenia gravisQMGravulizumab

Identifiers

PMID40309792
PMCPMC12026451

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.